Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of devimistat plus modified FOLFIRINOX versus FOLFIRINOX in metastatic pancreatic adenocarcinoma
MOH_2019-03-19_006038Phase 3Not yet recruiting
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of devimistat in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Cornerstone Pharmaceuticals. Primary endpoints: Progression-free survival and Objective response rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
devimistat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2019-03-19_006038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-19_006038.